PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ocumension Therapeutics  (1477.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG674111011
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$4.18B
Revenue (TTM)HK$246.37M
Gross Profit (TTM)HK$102.92M
EBITDA (TTM)-HK$375.05M
Year RangeHK$4.51 - HK$10.40
Target PriceHK$11.57

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with 1477.HK

Ocumension Therapeutics 

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Ocumension Therapeutics , comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%OctoberNovemberDecember2024FebruaryMarch
-84.51%
66.30%
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

S&P 500

Returns By Period

Ocumension Therapeutics  had a return of -14.22% year-to-date (YTD) and -37.38% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-14.22%10.04%
1 month11.70%3.53%
6 months-22.88%22.79%
1 year-37.38%32.16%
5 years (annualized)N/A13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-24.85%3.39%
2023-14.14%-7.38%0.65%-11.30%-2.20%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Ocumension Therapeutics  (1477.HK) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
1477.HK
Ocumension Therapeutics 
-0.80
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Ocumension Therapeutics  Sharpe ratio is -0.80. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.80
2.74
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

Dividends

Dividend History


Ocumension Therapeutics  doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-84.51%
0
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ocumension Therapeutics . A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ocumension Therapeutics  was 87.24%, occurring on Feb 5, 2024. The portfolio has not yet recovered.

The current Ocumension Therapeutics  drawdown is 84.51%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-87.24%Jul 13, 2020881Feb 5, 2024

Volatility

Volatility Chart

The current Ocumension Therapeutics  volatility is 13.64%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%OctoberNovemberDecember2024FebruaryMarch
13.64%
2.82%
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ocumension Therapeutics  over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items